Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submission of the LeukoStrat® CDx FLT3 Mutation Assay to the PMDA (Pharmaceuticals and Medical Devices Agency) as the companion diagnostic for quizartinib, which follows Daiichi Sankyo’s PMDA application for quizartinib in Japan.
Invivoscribe developed the LeukoStrat CDx FLT3 Mutation Assay in partnership with Daiichi Sankyo as the companion diagnostic that bridges to the global phase 3 QuANTUM-R clinical trial (Europe, United States, Asia excluding Japan) in patients with relapsed/refractory FLT3 ITD AML. Together, QuANTUM-R clinical trial and open-label phase 2 study of quizartinib (Japan) support the Daiichi Sankyo New Drug Application (NDA) to Japan’s MHLW/PMDA for marketing approval of quizartinib for the treatment of adult patients with relapsed/refractory FLT3 ITD acute myeloid leukemia (AML).
This submission complements Invivoscribe’s prior regulatory approvals of this LeukoStrat CDx FLT3 Mutation Assay as an AML companion diagnostic in support of midostaurin for Novartis (United States and Europe), and gilteritinib fumarate for Astellas (Japan). Astellas and Invivoscribe have also submitted applications for the drug and device to the CDER and CDRH, respectively, in the United States.
This milestone helps to further establish the LeukoStrat CDx FLT3 Mutation Assay as the international standard for comprehensive FLT3 assessment for critically ill acute myeloid leukemia patients as this CDx is available worldwide and generates standardized signal ratios for both ITD and TKD mutations. These criteria are already resulting in more consistent stratification of patients which will help prescribing doctors identify personalized therapy options for their patients and accelerate new drug and therapy approvals by establishing more homogeneous patient populations for clinical trials.
Timing of this submission also reflects the efficiencies of Invivoscribe’s Streamlined CDx ™ program, which provides pharmaceutical partners with integration of activities including CDx development, clinical trials support with rapid patient screening for enrollment, regulatory support and commercialization. Combining many of these activities can accelerate drug approvals as well as ensure rapid availability of the drugs to the appropriate patients following approvals.
“The LeukoStrat CDx FLT3 Mutation Assay Partial Change Approval Application submission and continuing Daiichi Sankyo partnership represent significant milestones for our company. We continue to welcome opportunities to partner with global pharmaceutical companies interested in developing and commercializing companion diagnostics, whether for hematologic disease or solid tumors,” said Jeffrey Miller, Invivoscribe’s CSO and CEO. “Invivoscribe remains focused on improving the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine.”
About the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay
The LeukoStrat CDx FLT3 Mutation Assay is a PCR-based, in vitro diagnostic test designed to detect internal tandem duplication (ITD) mutations and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with acute myelogenous leukemia. This globally standardized test includes software that interprets data, generates mutant/wildtype signal ratios for ITD and TKD mutations, and predicts response to both gilteritinib fumarate and midostaurin. This extensively validated assay helps standardize the detection of genetic mutations in the FLT3 gene as one of the most important driver mutations in Acute Myeloid Leukemia (AML). In serving as the companion diagnostic to the Daiichi Sankyo sponsored clinical trials, this test reports out FLT3 ITD mutations alone.
The LeukoStrat test is currently available as a test menu service through the Invivoscribe subsidiaries, LabPMM LLC (San Diego, CA, US), LabPMM GmbH (Martinsried, Germany) and LabPMM GK (Kawasaki City, Japan). LeukoStrat CDx FLT3 Mutation Assay kits are currently distributed in Europe. Distribution of kits in Japan, United States, and China are planned.
About Invivoscribe
Invivoscribe is a privately held biotechnology company dedicated to Improving Lives with Precision Diagnostics™. For nearly twenty-five years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies interested in developing and commercializing companion diagnostics, and provides expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM), Invivoscribe is an ideal partner from diagnostic development through clinical trials and regulatory submissions. For additional information please contact Invivoscribe at support@invivoscribe.com or visit www.invivoscribe.com.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Investeringsforvaltningsaftale med BI Management A/S er godkendt af Finanstilsynet19.3.2024 13:15:48 CET | pressemeddelelse
PFA Asset Management A/S offentliggjorde i selskabsmeddelelse af 22. januar 2024, at Investeringsforeningen PFA Invests (”Foreningen”) bestyrelse havde besluttet at udpege BI Management A/S som investeringsforvaltningsselskab for Foreningen. Finanstilsynet har godkendt valget af BI Management A/S som nyt investeringsforvaltningsselskab for Foreningen. BI Management A/S vil overtage rollen som investeringsforvaltningsselskab seneste ved udgangen af andet kvartal 2024. Eventuel henvendelse vedrørende denne meddelelse kan rettes til direktør Rasmus Bessing. Med venlig hilsen PFA Asset Management A/S Rasmus Bessing Direktør
Offentliggørelse af bestyrelsens redegørelse19.3.2024 13:05:00 CET | pressemeddelelse
Selskabsmeddelelse nr. 8-2023/24 19. marts 2024 MÅ IKKE OFFENTLIGGØRES, PUBLICERES ELLER UDLEVERES DIREKTE ELLER INDIREKTE I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF GÆLDENDE LOVGIVNING ELLER REGLER I DEN PÅGÆLDENDE JURISDIKTION, HERUNDER I USA Offentliggørelse af bestyrelsens redegørelse Med henvisning til InterMail A/S' ("InterMail") meddelelse af 5. marts 2024 (nr. 7-2023/24) om offentliggørelse af tilbudsdokumentet vedrørende det frivillige offentlige overtagelsestilbud på InterMail fremsat af CapHold 4 inv ApS ("Tilbuddet"), offentliggør InterMail i dag bestyrelsens redegørelse om Tilbuddet ("Redegørelsen") i henhold til § 22 i bekendtgørelse nr. 636/2020 om overtagelsestilbud. Redegørelsen indeholder bestyrelsens holdning til tilbuddet og begrundelsen herfor, herunder bestyrelsens holdning til konsekvenserne for alle selskabets interessenter og til tilbudsgivers strategiske planer for målselskabet samt disses sandsynlige konsekvenser for beskæftige
Zoom Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 202419.3.2024 13:04:05 CET | Press release
SAN JOSE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Zoom Video Communications, Inc. (NASDAQ: ZM), has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2024. This year’s list shines a spotlight on businesses that are shaping industry and culture through their innovations. These organizations are setting new standards and achieving remarkable milestones in all sectors of the economy. Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 606 organizations across 58 sectors and regions. “At Zoom, we continue to innovate rapidly and are doubling down on our commitment to offering an AI-powered collaboration platform that delivers limitless human connection, reimagines teamwork, and strengthens customer connections,” said Smita Hashim, chief product officer at Zoom. “Fast Company’s recognition further validates our mission and dedication to providing our customers with choice and a high-quality, open collaboration platform power
RevoluPay Announces Strategic Agreement with SHIFT Financial Services Ltd.19.3.2024 13:00:00 CET | Press release
Vancouver, BC, March 19, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) (the "Company") is pleased to announce that RevoluGROUP, through its wholly owned subsidiary RevoluPAY, has entered into a strategic collaboration with SHIFT Financial Services Ltd. (“SHIFT”). This collaboration offers SHIFT intermediary transfer solutions for core, high-value, and high-margin payment transactions, leveraging the RevoluPAY innovative multi-currency payment solutions catering to the dynamic needs of global businesses and consumers. "Our collaboration with SHIFT is a testament to our commitment to providing top-tier financial solutions that meet the evolving demands of the global market," commented Alfred Manresa, Director of RevoluGROUP and General Manager of RevoluPAY. "Together, we are setting a new standard for multi-currency transactions, driving the digital payments revolution forward." The agreement sets forth a detailed operational framewor
Ensurge Micropower Asa - Key Information Relating to Share Consolidation and Change of Isin19.3.2024 12:54:36 CET | Press release
Reference is made to the Extraordinary General Meeting in Ensurge Micropower ASA (the "Company"), held today, whereby all proposed resolutions were approved. Key information relating to the approved share consolidation: Date on which the terms and conditions of the share consolidation was made public: 19 March 2024; Share consolidation ratio: 5 old shares give 1 new share; Last day including right: 4 April 2024; Ex-date: 5 April 2024; Record date: 8 April 2024; Date of approval: 19 March 2024. In connection with the share consolidation, the Company's shares will be transferred to a new ISIN. Please find below the key information for the change of ISIN: Issuer: Ensurge Micropower ASA Old ISIN: NO0012450008 New ISIN: NO0013186460 Date of ISIN change: 5 April 2024 This information is published in accordance with the requirements of the Continuing Obligations.